"We have been very busy working on new development
Post# of 36729
Posted On: 05/07/2014 10:04:15 PM
"We have been very busy working on new developments with the Dharma Care and Hospice Program. The program has grown considerably in the last few months. There are currently over 100 patients who qualify for free meds..."
For starters... And at risk of sounding like a dick, which I'm not afraid to do, the above statement says to me that they have been busy helping sick people get free medicine. That's great for Mother Theresa, how does is help the public company generate revenue? I'm sorry that sounds harsh, I'm just looking for signs of collected revenue on the books.
The kind banker thinks that this...
"Please note that all Berkeley Bio products, and all YAK products, offered by Dharma are part of SK3’s managed collective program and the revenues therefrom are reflected in the SK3 financials."
...means the Dharma program is an expense that is paid for by those buying YAK products...and that it's all reflected on the financials.
If the AR from the initial contracts is not being collected, we really need every sale of BBIO products to hit the bottom line directly.
I recently asked a question on the BBIO page about "how many bottles of Dharmanol have been sold?"
I believe this is how Dave answered that question...
"Because we have the YAK Capsules available in hundreds of California dispensaries, we feel that we can take our time somewhat in perfecting our new offerings, because the market for them is being fulfilled with the YAK capsules currently, which generate substantial ongoing revenues, and have done so for about six years."
There you go. IMO Dave's good faith effort at wordsmithing some transparency.
For starters... And at risk of sounding like a dick, which I'm not afraid to do, the above statement says to me that they have been busy helping sick people get free medicine. That's great for Mother Theresa, how does is help the public company generate revenue? I'm sorry that sounds harsh, I'm just looking for signs of collected revenue on the books.
The kind banker thinks that this...
"Please note that all Berkeley Bio products, and all YAK products, offered by Dharma are part of SK3’s managed collective program and the revenues therefrom are reflected in the SK3 financials."
...means the Dharma program is an expense that is paid for by those buying YAK products...and that it's all reflected on the financials.
If the AR from the initial contracts is not being collected, we really need every sale of BBIO products to hit the bottom line directly.
I recently asked a question on the BBIO page about "how many bottles of Dharmanol have been sold?"
I believe this is how Dave answered that question...
"Because we have the YAK Capsules available in hundreds of California dispensaries, we feel that we can take our time somewhat in perfecting our new offerings, because the market for them is being fulfilled with the YAK capsules currently, which generate substantial ongoing revenues, and have done so for about six years."
There you go. IMO Dave's good faith effort at wordsmithing some transparency.
(0)
(0)